| 苏林燕.英夫利西单抗辅助治疗成人克罗恩病的临床疗效及对生存质量的影响[J].浙江中西医结合杂志,2018,28(5): |
| 英夫利西单抗辅助治疗成人克罗恩病的临床疗效及对生存质量的影响 |
| Clinical effect of infliximab for the adjuvant treatment of adult Crohn"s disease and its effect on quality of life |
| 投稿时间：2017-07-18 修订日期：2017-09-26 |
| DOI： |
| 中文关键词: 英夫利西单抗 克罗恩病 临床疗效 生存质量 不良反应 |
| 英文关键词:Infliximab Crohn"s disease Clinical efficacy Quality of life Adverse reactions |
| 基金项目: |
|
| 摘要点击次数: 940 |
| 全文下载次数: 4 |
| 中文摘要: |
| 目的 探讨英夫利西单抗辅助治疗成人克罗恩病的临床效果,并评估对患者生存质量的改善作用。方法 选择本院2015年1月至2016年5月克罗恩病患者74例,根据入院编号随机分为对照组(37例)和治疗组(37例)。对照组患者给予常规治疗,治疗组在常规治疗基础上给予英夫利西单抗治疗。观察两组临床疗效和不良反应,评估治疗前后克罗恩病疾病活动指数(CDAI),应用炎症性肠病生存质量问卷(IBDQ) 评估治疗前后患者的生存质量。结果 治疗组总有效率为94.59%(35/37),高于对照组81.08%(30/37),治疗组治疗后疾病活动程度好转率为91.89%(34/37),高于对照组78.38%(29/37),差异有统计学意义(P＜0.05),治疗组治疗后CDAI评分为(154.31±32.77)分,低于对照组(170.84±35.30)分,差异有统计学意义(P＜0.05),治疗组治疗后IBDQ总分为(188.47±20.15)分,高于对照组治疗后(171.66±19.12)分,差异有统计学意义(P＜0.05)。结论 英夫利西单抗辅助治疗成人克罗恩病临床疗效显著,患者生存质量得到显著改善,并具有较好的安全性。 |
| 英文摘要: |
| Objective To explore the clinical efficacy of infliximab for the adjuvant treatment of adult Crohn"s disease and to evaluate the improvement of quality of life. Methods Forty-seven patients with Crohn"s disease were selected from January in 2015 to May in 2016 and were randomly divided into control group (37) and treatment group (37) according to admission number. Patients of the control group were given conventional therapy and the treatment group was given adjuvant infliximab basis on the routine treatment. To observe the clinical efficacy and side effects of the two groups,and to assess Crohn"s disease disease activity index (CDAI) before and after the treatment, the use of inflammatory bowel disease quality of life questionnaire (IBDQ) to assess the quality of life before and after treatment. Results The total effective rate of the treatment group was 94.59% (35/37),higher than the control group 81.08% (30/37) ,the improvement rate of disease activity of the treatment group was 91.89% (34/37), which was higher than that in the control group 78.38%(29/37),the difference was statistically significant (P<0.05).The CDAI scores of the treatment group was (154.31±32.77)points, which was lower than that in the control group (170.84±35.30) points, the difference was statistically significant (P <0.05). The total score of IBDQ in the treatment group was (188.47±20.15) points, which was higher than that of the control group (171.66±19.12) points,the difference was statistically significant (P<0.05).Conclusion It has the better clinical treatment effective of infliximab monotherapy for adjuvant treatment of adult Crohn"s disease.And the quality of life was significantly improved and had better safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
